International Journal of Hematological Disorders
ISSN (Print): ISSN Pending ISSN (Online): ISSN Pending Website: http://www.sciepub.com/journal/ijhd Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
International Journal of Hematological Disorders. 2014, 1(1A), 7-12
DOI: 10.12691/ijhd-1-1A-2
Open AccessResearch Article

Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma?

Morie A. Gertz1, , Francis K. Buadi1 and Martha Q. Lacy1

1Department of Medicine, College of Medicine, Mayo Distinguished Clinician, Rochester

Pub. Date: December 09, 2014
(This article belongs to the Special Issue Plasma cell disorders )

Cite this paper:
Morie A. Gertz, Francis K. Buadi and Martha Q. Lacy. Is There Still a Role for High-Dose Melphalan and Stem Cell Transplantation in the Treatment of Multiple Myeloma?. International Journal of Hematological Disorders. 2014; 1(1A):7-12. doi: 10.12691/ijhd-1-1A-2

Abstract

Stem cell transplantation was demonstrated to have a survival value in the era prior to the introduction of novel agents for the treatment of multiple myeloma. It has become reasonable to begin to question the value of stem cell transplantation. In this review, we analyzed available data and ongoing trials to determine whether or not the evidence is sufficient to continue using stem cell transplantation as a primary modality for the treatment of the eligible patient with multiple myeloma.

Keywords:
high-dose melphalan stem cell transplantation multiple myeloma bortezomib lenalidomide; thalidomide

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Offidani M, Leoni P, Corvatta L, Polloni C, Gentili S, Liberati AM, Pulini S, Gozzetti A, Ballanti S, Nozzoli C, Palumbo A. “Outcome and toxicity in the modern era of new drugs for multiple myeloma: a reappraisal for comparison with future investigational trials,” Clin Lymphoma Myeloma Leuk, 10 (5), 353-60, 2010.
 
[2]  Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, et al. “A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma,” Blood, 120 (9), 1801-9, 2012.
 
[3]  Anderson K. “Multiple myeloma: advances reported in 2013 are useful in the clinic,” J Natl Compr Canc Netw, 12 (5 Suppl), 808-11, 2014.
 
[4]  Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, et al. “Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients,” Leukemia, 28 (5), 1122-8, 2014.
 
[5]  Atanackovic D, Schilling G. “Second autologous transplant as salvage therapy in multiple myeloma,” Br J Haematol, 163 (5), 565-72, 2013.
 
[6]  Gertz MA, Lacy MQ. “Salvage autologous stem cell transplant is an effective regimen for relapsed multiple myeloma,” Leuk Lymphoma, 54 (10), 2096-7, 2013.
 
[7]  Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R. “A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome,” N Engl J Med, 335 (2), 91-7, 1996.
 
[8]  Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. “High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma,” N Engl J Med, 348 (19), 1875-83, 2003.
 
[9]  Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. “Antitumor activity of thalidomide in refractory multiple myeloma,” N Engl J Med, 341 (21), 1565-71, 1999.
 
[10]  Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X, Boccacio C, Brouet JC. “High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial,” Blood, 92 (9), 3131-6, 1998.
 
[11]  McCarthy PL, Palumbo A. “Maintenance therapy for multiple myeloma,” Hematol Oncol Clin North Am, 28 (5), 839-59, 2014.
 
[12]  Kumar SK, Lacy MQ, Dispenzieri A, Buadi FK, Hayman SR, Dingli D, Gay F, Sinha S, Leung N, Hogan W, Rajkumar SV, Gertz MA. “Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma,” Cancer, 118 (6), 1585-92, 2012.
 
[13]  Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. “The Arkansas approach to therapy of patients with multiple myeloma,” Best Pract Res Clin Haematol, 20 (4), 761-81, 2007.
 
[14]  Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, et al. “Long-term outcome results of the first tandem autotransplant trial for multiple myeloma,” Br J Haematol, 135 (2), 158-64, 2006.
 
[15]  Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, Garcia-Larana J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, et al. “Long-term prognostic significance of response in multiple myeloma after stem cell transplantation,” Blood, 118 (3), 529-34, 2011.
 
[16]  Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, et al. “Clonal competition with alternating dominance in multiple myeloma,” Blood, 120 (5), 1067-76, 2012.
 
[17]  Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, et al. “Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides,” Blood, 120 (5), 1060-6, 2012.
 
[18]  Bahlis NJ. “Darwinian evolution and tiding clones in multiple myeloma,” Blood, 120 (5), 927-8, 2012.
 
[19]  Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, Fryer RA, Johnson DC, Begum DB, Hulkki Wilson S, Vijayaraghavan G, Titley I, et al. “Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma,” Leukemia, 28 (8), 1705-15, 2014.
 
[20]  Hajek R, Okubote SA, Svachova H. “Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma,” Br J Haematol, 163 (5), 551-64, 2013.
 
[21]  Hosen N. “Multiple myeloma-initiating cells,” Int J Hematol, 97 (3), 306-12, 2013.
 
[22]  Gourzones-Dmitriev C, Kassambara A, Sahota S, Reme T, Moreaux J, Bourquard P, Hose D, Pasero P, Constantinou A, Klein B. “DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment,” Cell Cycle, 12 (17), 2760-73, 2013.
 
[23]  Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM, Jr., Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, et al. “Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma,” Leuk Lymphoma, 54 (8), 1658-64, 2013.
 
[24]  Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR, Buadi FK, Hogan WJ. “Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction,” Blood, 115 (12), 2348-53; quiz 560, 2010.
 
[25]  Barlogie B, Mitchell A, van Rhee F, Epstein J, Morgan GJ, Crowley J. “Curing myeloma at last: defining criteria and providing the evidence,” Blood,2014.
 
[26]  Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, et al. “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” Lancet, 376 (9758), 2075-85, 2010.
 
[27]  Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, et al. “Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial,” J Clin Oncol, 30 (24), 2946-55, 2012.
 
[28]  Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, Russell SJ, Hayman SR, Witzig TE, Lust JA, Leung N, Lin Y, et al. “Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma,” J Clin Oncol, 31 (36), 4529-35, 2013.
 
[29]  Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, Larana JG, Bengoechea E, et al. “Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma,” J Clin Oncol, 29 (12), 1627-33, 2011.
 
[30]  Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, de Las Heras N, Mateos MV, et al. “Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation,” Blood, 112 (10), 4017-23, 2008.
 
[31]  Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, et al. “Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma,” Biol Blood Marrow Transplant, 19 (11), 1615-24, 2013.
 
[32]  Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, Johnston PB, Kumar S, et al. “Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative,” Mayo Clin Proc, 83 (10), 1131-8, 2008.
 
[33]  McCarthy PL, Jr., Hahn T, Hassebroek A, Bredeson C, Gajewski J, Hale G, Isola L, Lazarus HM, Lee SJ, Lemaistre CF, Loberiza F, Maziarz RT, et al. “Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age,” Biol Blood Marrow Transplant, 19 (7), 1116-23, 2013.
 
[34]  Al-Hamadani M, Hashmi SK, Go RS. “Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents,” Am J Hematol, 89 (8), 825-30, 2014.
 
[35]  Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B, AlSayed Y, Vanrhee F, Barlogie B. “Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?,” Leukemia, 27 (1), 226-32, 2013.
 
[36]  diCapua Siegel DS, Jacobus S, Rajkumar SV, Abonour R, Callander NS, Katz MS, Fonseca R, Vesole DH. “Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial (Abstract 38),” Blood (ASH Annual Meeting Abstracts), 116 38, 2010.
 
[37]  Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, et al. “Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma,” Blood, 116 (5), 679-86, 2010.
 
[38]  Gay F, Cavallo F, Caravita T, Cavalli M, Nagler A, Montefusco V, Pogliani EM, Buttignol S, Zamagni E, Palladino C, Marcatti M, Musto P, et al. “Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients (Abstract 2089),” Blood 122 2089, 2013.
 
[39]  Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C, Ribakovsky E, Genuardi M, Cafro A, et al. “Autologous transplantation and maintenance therapy in multiple myeloma,” N Engl J Med, 371 (10), 895-905, 2014.
 
[40]  Palumbo A, Gay F, Spencer A, Di Raimondo F, Zdenek A, Larocca A, Falcone AP, Catalano L, Finsinger P, Vlastimil S, Aschero S, Offidani M, et al. “A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients (Abstract 763),” Blood, 122 763, 2013.
 
[41]  Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Yong K, Cavet J, Hunter H, et al. “High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial,” Lancet Oncol, 15 (8), 874-85, 2014.